Estrogen Therapy Linked to 39% Lower Dementia Risk
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Jennifer Bruno of Stanford Medicine led the analysis of 21,462 women, finding hormone therapy users had 39% lower odds of receiving a clinical dementia diagnosis and were less likely to show memory problems or declines in everyday functioning.
- Hormone therapy users had 35% lower odds of Alzheimer's-related brain changes at autopsy, after adjusting for age, education, genetics, race and hypertension.
- Among 2,959 autopsied participants (average age 82), 18% of hormone therapy users showed no signs of Alzheimer's disease versus 10% of non-users, while 40% of users had all three pathology signs (amyloid plaques, tau tangles, neuritic plaques) versus 51% of non-users.
- Biomarker tests on blood and spinal fluid from 728 participants during life showed amyloid levels consistent with less amyloid accumulating in the brains of hormone therapy users.
- The study, published in Neurology on August 12, 2026, focused exclusively on estrogen-only therapy because earlier research suggested estrogen combined with progestin may raise dementia risk; under current practice, estrogen-only therapy is prescribed only to women who have had a hysterectomy.
- Study participants began hormone therapy at an average age of 70 — decades later than the current standard of starting in the late 40s to early 50s and stopping before 60, a limitation Bruno flagged as central to interpreting the results.
- Bruno emphasized the findings show only an association, not causation, and said more research is needed before recommendations can be made about hormone therapy and brain health; the study was supported by the National Institute on Aging.
Why it matters: The 39% lower dementia odds and 35% lower odds of Alzheimer's pathology are among the larger associations reported in hormone-therapy research, but Bruno explicitly warned the women in this study started therapy at an average age of 70 — far later than today's prescribing window — meaning the findings are a clue for researchers, not yet guidance for the women actually weighing hormone therapy with their doctors.
Ask SkimNews
